


PHARMACEUTICAL 2021



Liquidia Corp Rank 205 of 402







PHARMACEUTICAL 2021



Liquidia Corp Rank 205 of 402

The relative strengths and weaknesses of Liquidia Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Liquidia Corp compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 28% points. The greatest weakness of Liquidia Corp is the variable Net Income, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 98%, being 50% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	66,069
Cost of Goods Sold	0
Intangible Assets	9,438
Liabilities, Current	11,737
Liabilities, Non-Current	15,299
Other Assets	17,219
Other Compr. Net Income	0
Other Expenses	238
Other Liabilities	1,410
Other Net Income	-674
Other Revenues	740
Property and Equipment	6,806
Research and Development	32,222
Selling, General and Administrative Expense	27,369

Output Variable	Value in 1000 USD
Assets	99,532
Liabilities	28,446
Expenses	59,829
Revenues	740
Stockholders Equity	71,086
Net Income	-59,763
Comprehensive Net Income	-59,763
Economic Capital Ratio	98%

